I have SMA. Critics of the $2 million new therapy are missing the point
I was perplexed and disappointed that the recent approval of Novartis’ gene therapy Zolgensma was immediately overshadowed by outrage over the drug’s price.
Related Articles
The infamous ‘Cutter vaccine’ changed my family forever — but we still support vaccination
Laurie Maffly-Kipp’s aunt contracted polio in the infamous Cutter Incident. But her family sees it as a story about in the ability of science to…
JPM dispatches: Nvidia, Recursion, Dexcom and more
The latest edition of STAT’s Health Tech newsletter brings you important dispatches from the J.P. Morgan Health Care conference.
The Supreme Court considers another challenge to the ACA
This week in health care politics and policy: Another ACA case at the Supreme Court, a CMS staffing pick, and RFK Jr.’s biotech bets.
A biotech legend, pharma CEO, and two Trump admin vets walk into JPM Day 2
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hey there. This is…
Eli Lilly CEO says the company sees ‘significant common cause’ with Trump administration
Eli Lilly CEO said he believed the company could find “significant common cause” with the Trump administration, even if there were reasons for concern.
Beyond BMI: New report reframes obesity as a spectrum of illness, not just a risk factor
A Lancet commission downplays BMI and calls for “preclinical” and “clinical” categories of obesity.
Will the MAHA movement include alcohol among its targets?
We explore the MAHA movement and sobriety, and a shift to ‘natural’ birth control, while an opinion writer says it’s possible to make raw milk…
No longer a rocket ship, Teladoc promises stability to impress investors
After years of rapid growth, virtual care company Teladoc promises stability to win over skeptical investors. #JPM25
NIH issues a policy to widen access to medical products that emerge from government-funded research
NIH policy asks companies seeking licenses to sell medical products invented with government research to submit plans for ensuring greater access to patients.
Federal watchdog raises some concerns about the FDA’s accelerated approval program
The Office of the Inspector General reviewed the FDA’s use of accelerated approval for 24 drugs, ultimately finding issues with the process for three of…